Jiangsu Hengrui Medicine announced China regulators approved its PD-1 drug, camrelizumab, as a third-line treatment for recurrent or refractory classical Hodgkin’s lymphoma. Camrelizumab is the third domestic PD-1/PD-L1 drug approved in China; previously, Junshi's Tuoyi and Innovent's Tyvyx were granted marketing approvals. Two US-based companies have also entered China's PD-1/PD-L1 market -- Merck with Keytruda (also for melanoma) and Bristol Myers Squibb with Opdivo. Hengrui said it is testing camrelizumab in about 20 China clinical trials. More details....
Stock Symbol: (SHA: 600276)
Share this with colleagues:
Original Article: Hengrui Medicine's PD-1 Drug Approved in China for Lymphoma